November 6, 2024
In an interview with Genetic Engineering & Biotechnology News, Senior Director, CMC, Kiren Khanduja highlights how Pheast Therapeutics is applying a parallel platform-based CMC strategy to accelerate development of its anti-CD24 macrophage checkpoint inhibitor, PHST001, ultimately compressing timelines in half. Khanduja underscores how this agile manufacturing approach supports Pheast’s broader strategy to rapidly advance macrophage checkpoint therapies, positioning PHST001 for efficient clinical development and scalable production.
Read the full article here.